Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-Ablative Conditioning for Allogeneic Stem Cell Transplant
NCT00008307Phase 2
Key facts
- Status
- Unknown
- Start
- Apr 1998
- Countries
- 1
- Sponsor
- Herbert Irving Comprehensive Cancer Center
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Drugs
- fludarabinemelphalan
- Conditions
- leukemialymphomamultiple myeloma (MM)myelodysplastic syndrome (MDS)aplastic anemia
01
Overview
Phase 2, open-label, single-arm trial of fludarabine and melphalan in leukemia, lymphoma, multiple myeloma (MM) and 5 more, sponsored by Herbert Irving Comprehensive Cancer Center. Primary endpoints: Hematopoietic recovery and Incidence of graft-versus-host disease. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Non-Ablative Conditioning
Fludarabine + Melphalan followed by Allogeneic SCT
03
Who it enrols
Patients with confirmed hematologic malignancy (CML, AML, ALL, MDS, Lymphoma, MM) or genetic disorder (e.g., storage disease, hemoglobinopathy, immunodeficiency) who are unwilling or unable to undergo conventional high-dose conditioning. Must have a suitable donor.
04
Endpoints
Primary
Hematopoietic recovery
Incidence of graft-versus-host disease
Secondary
Chemotherapeutic toxicity
Relapse
Survival
Beyond the preview
Go deeper on NCT00008307.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00008307.